Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors Abstract #178

Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.
Aim(s): To report our experience with 177Lutetium-DOTA-Tyr3-octreotate in patients with malignant neuroendocrine tumors.
Materials and methods: Two-hundred and thirty-one patients; 96 midgut, 13 lung, 18 rectal, 44 non-functioning EPT, nine gastrinomas, six glucagonomas, two insulinomas, eight pheo/paragangliomas, 35 other, have each received 1–8 treatments, decided by dosimetry, with 6–12 weeks’ interval. Almost all progressed on prior therapy. One-hundred and ninety patients were evaluated with CT/MRI. Mean follow-up was 13.3 months (2–57).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ass Prof Dan Granberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT
Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Sofie Van Binnebeek
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
#1416 Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Advanced Bronchial Neuroendocrine Tumours
Introduction: There is not established treatment pathway in advanced bronchial neuroendocrine tumours(bNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
Keywords: PRRT, bronchial NETs
#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures
Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: doctor Corinne Gerard